MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Agios Pharmaceuticals Company Profile (NASDAQ:AGIO)

Consensus Ratings for Agios Pharmaceuticals (NASDAQ:AGIO) (?)
Ratings Breakdown: 7 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Hold (Score: 2.42)
Consensus Price Target: $78.80 (60.98% upside)

Analysts' Ratings History for Agios Pharmaceuticals (NASDAQ:AGIO)
Show:
DateFirmActionRatingPrice TargetActions
4/25/2016Credit SuisseReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/31/2016JPMorgan Chase & Co.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/29/2016SunTrustInitiated CoverageBuy$57.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/4/2016Canaccord GenuityReiterated RatingHold$70.00 -> $50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/1/2016Janney Montgomery ScottInitiated CoverageNeutral$43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman SachsLower Price Target$72.00 -> $47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016Leerink SwannReiterated RatingMarket Perform$62.00 -> $56.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/9/2015Roth CapitalLower Price TargetNeutral$114.00 -> $75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/9/2015OppenheimerReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/22/2015Northland SecuritiesInitiated CoverageOutperform$132.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/2/2015DesjardinsUpgradeHold -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2015Citigroup Inc.Initiated CoverageNeutral$132.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2015MLV & Co.Initiated CoverageBuy$130.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/1/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha